

**WE CLAIM:**

- Sub B1*
1. A method of treating obesity comprising administering to an obese subject a therapeutically effective amount of a PYY or a PYY agonist.
- 
- 5      2. The method of claim 1 wherein the subject is at least one of insulin resistant or glucose intolerant.
3. The method of claim 1 wherein the subject has diabetes mellitus.
- 10      4. The method of claim 1 wherein the PYY agonist is PYY[3-36].
5. The method of claim 1 wherein the PYY or PYY agonist is administered peripherally.
- 
- Sub B2*
- 15      6. The method of claim 1 wherein about 1  $\mu$ g to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.
7. The method of claim 1 wherein about 0.01  $\mu$ g/kg to about 500  $\mu$ g/kg of the PYY or PYY agonist is administered per dose.
- 20      8. A method of reducing food intake comprising administering to a subject a therapeutically effective amount of a PYY or a PYY agonist.
- 
9. The method of claim 8 wherein the PYY agonist is PYY[3-36].
- 25      10. The method of claim 8 wherein the PYY or PYY agonist is administered peripherally.
- 
- Sub B3*
- 30      11. The method of claim 8 wherein about 1  $\mu$ g to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.
12. The method of claim 8 wherein about 0.01  $\mu$ g/kg to about 500  $\mu$ g/kg of the PYY or PYY agonist is administered per dose.
-

13. A method of treating diabetes mellitus in a subject comprising administering an effective amount of a PYY or a PYY agonist.

5 14. The method of claim 13 wherein the PYY or PYY agonist is administered peripherally.

15. The method of claim 13 wherein the subject has Type II diabetes.

10 16. The method of claim 13 wherein the subject is overweight.

17. The method of claim 13 wherein the PYY agonist is PYY[3-36].

15 18. The method of claim 13 wherein about 1  $\mu$ g to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.

19. The method of claim 13 wherein about 0.01  $\mu$ g/kg to about 500  $\mu$ g/kg of the PYY or PYY agonist is administered per dose.

20 20. A method of improving lipid profile in a subject comprising administering to the subject an effective amount of a PYY or a PYY agonist.

25 21. The method of claim 20 wherein the improvement in lipid profile comprises at least one of reducing LDL cholesterol levels, reducing triglyceride levels and increasing HDL cholesterol levels.

22. The method of claim 20 wherein the PYY or PYY agonist is administered peripherally.

*Sub 34* 23. A method for treating conditions or disorders which can be alleviated by reducing nutrient availability in a subject comprising administering to said subject a therapeutically effective amount of a PYY or a PYY agonist.

5 24. The method of claim 23 wherein the condition or disorder is hypertension.

25. The method of claim 23 wherein the condition or disorder is dyslipidemia.

26. The method of claim 23 wherein the condition is cardiovascular risk.

10

27. The method of claim 23 wherein the disorder is an eating disorder.

28. The method of claim 23 wherein the condition or disorder is insulin-resistance.

15

29. The method of claim 23 wherein the condition is obesity.

30. The method of claim 23 wherein the condition is diabetes mellitus.

*Sub 20* 31. The method of claim 23 wherein about 1  $\mu\text{g}$  to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.

32. The method of claim 23 wherein about 0.01  $\mu\text{g}/\text{kg}$  to about 500  $\mu\text{g}/\text{kg}$  of the PYY or PYY agonist is administered per dose.

*Sub 25* 33. The method of any of claims 1, 8, 13, 20, and 23 wherein the PYY agonist has a potency in at least one of a food intake or gastric emptying assay greater than NPY.